563 related articles for article (PubMed ID: 16892428)
21. Planned versus provisional use of glycoprotein IIb/IIIa inhibitors in smokers undergoing percutaneous coronary intervention.
Robertson JO; Lincoff AM; Wolski K; Topol EJ
Am J Cardiol; 2006 Jun; 97(12):1679-84. PubMed ID: 16765113
[TBL] [Abstract][Full Text] [Related]
22. Bivalirudin during primary PCI in acute myocardial infarction.
Stone GW; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Dangas G; Wong SC; Kirtane AJ; Parise H; Mehran R;
N Engl J Med; 2008 May; 358(21):2218-30. PubMed ID: 18499566
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
White HD; Ohman EM; Lincoff AM; Bertrand ME; Colombo A; McLaurin BT; Cox DA; Pocock SJ; Ware JA; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Stone GW
J Am Coll Cardiol; 2008 Sep; 52(10):807-14. PubMed ID: 18755342
[TBL] [Abstract][Full Text] [Related]
24. Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
Chacko M; Lincoff AM; Wolski KE; Cohen DJ; Bittl JA; Lansky AJ; Tsuchiya Y; Betriu A; Yen MH; Chew DP; Cho L; Topol EJ
Am Heart J; 2006 May; 151(5):1032.e1-7. PubMed ID: 16644331
[TBL] [Abstract][Full Text] [Related]
25. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
[TBL] [Abstract][Full Text] [Related]
26. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).
Chew DP; Lincoff AM; Gurm H; Wolski K; Cohen DJ; Henry T; Feit F; Topol EJ;
Am J Cardiol; 2005 Mar; 95(5):581-5. PubMed ID: 15721095
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention.
Summers KM; Holdford DA; Crouch MA
Pharmacotherapy; 2006 May; 26(5):609-18. PubMed ID: 16637790
[TBL] [Abstract][Full Text] [Related]
28. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW;
JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378
[TBL] [Abstract][Full Text] [Related]
29. Temporal trends, safety, and efficacy of bivalirudin in elective percutaneous coronary intervention: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium.
Gurm HS; Smith DE; Chetcuti SJ; Share D; Khanal S; Riba A; Carter AJ; Lalonde T; Kline-Rogers E; O'Donnell M; O'Neill W; Safian R; Moscucci M;
J Interv Cardiol; 2007 Jun; 20(3):197-203. PubMed ID: 17524111
[TBL] [Abstract][Full Text] [Related]
30. Short- and long-term outcomes in diabetes patients undergoing percutaneous coronary intervention with bivalirudin compared with heparin and glycoprotein IIb/IIIA inhibitors: A meta-analysis of randomized trials.
Nairooz R; Sardar P; Amin H; Chatterjee S; Helmy T; Naidu SS
Catheter Cardiovasc Interv; 2015 Sep; 86(3):364-75. PubMed ID: 25914388
[TBL] [Abstract][Full Text] [Related]
31. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials.
Mehran R; Pocock S; Nikolsky E; Dangas GD; Clayton T; Claessen BE; Caixeta A; Feit F; Manoukian SV; White H; Bertrand M; Ohman EM; Parise H; Lansky AJ; Lincoff AM; Stone GW
JACC Cardiovasc Interv; 2011 Jun; 4(6):654-64. PubMed ID: 21700252
[TBL] [Abstract][Full Text] [Related]
32. Head-to-head comparison of bivalirudin versus heparin without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing primary angioplasty.
Bonello L; de Labriolle A; Roy P; Steinberg DH; Pinto Slottow TL; Xue Z; Kaneshige K; Torguson R; Suddath WO; Satler LF; Kent KM; Pichard AD; Waksman R
Cardiovasc Revasc Med; 2009; 10(3):156-61. PubMed ID: 19595396
[TBL] [Abstract][Full Text] [Related]
33. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
Stone GW; Bertrand M; Colombo A; Dangas G; Farkouh ME; Feit F; Lansky AJ; Lincoff AM; Mehran R; Moses JW; Ohman M; White HD
Am Heart J; 2004 Nov; 148(5):764-75. PubMed ID: 15523305
[TBL] [Abstract][Full Text] [Related]
34. Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (A REPLACE-2 analysis).
Gibson CM; Ten Y; Murphy SA; Ciaglo LN; Southard MC; Lincoff AM; Waksman R
Am J Cardiol; 2007 Jun; 99(12):1687-90. PubMed ID: 17560876
[TBL] [Abstract][Full Text] [Related]
35. Can bivalirudin and provisional GP IIb/IIIa blockade REPLACE heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention?
Doggrell S
Expert Opin Pharmacother; 2003 Aug; 4(8):1431-3. PubMed ID: 12877649
[TBL] [Abstract][Full Text] [Related]
36. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.
Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR
Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331
[TBL] [Abstract][Full Text] [Related]
37. Comparison of patient outcomes with bivalirudin versus unfractionated heparin in percutaneous coronary intervention.
Watson K; Seybert AL; Saul MI; Lee JS; Kane-Gill SL
Pharmacotherapy; 2007 May; 27(5):647-56. PubMed ID: 17461699
[TBL] [Abstract][Full Text] [Related]
38. [Clinical and economical evaluation of bivalirudin during percutaneous coronary interventions].
Caruba T; Chaïb A; Danchin N; Rahal S; Bégué D; Durand E; Prognon P; Lafont A; Sabatier B
Ann Cardiol Angeiol (Paris); 2010 Apr; 59(2):72-8. PubMed ID: 19962685
[TBL] [Abstract][Full Text] [Related]
39. Bivalirudin versus unfractionated heparin in patients undergoing percutaneous coronary intervention after acute myocardial infarction.
Chu WW; Kuchulakanti PK; Wang B; Torguson R; Clavijo LC; Pichard AD; Suddath WO; Satler LF; Kent KM; Waksman R
Cardiovasc Revasc Med; 2006; 7(3):132-5. PubMed ID: 16945819
[TBL] [Abstract][Full Text] [Related]
40. Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: a meta-analysis of randomized clinical trials.
Lee MS; Liao H; Yang T; Dhoot J; Tobis J; Fonarow G; Mahmud E
Int J Cardiol; 2011 Nov; 152(3):369-74. PubMed ID: 20843568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
